Publications supported by LLS Research – March 2021

In the month of March, we have identified 63 peer-reviewed publications that cited support from the leukemia and Lymphoma Society through our various Research Grants programs!

We apologize if you are not featured on this list and you feel you should be - please e-mail your Program Lead or the Grant Administration Team at [email protected] to alert us to your new publication.

Several of our Therapy Acceleration Program® partners presented new data during the 2021 Annual Meeting of the American Association for Cancer Research (AACR) in April.

  • Alibhai, S.M.H., H. Breunis, J. Matelski, N. Timilshina, A. Kundra, C.H. Lee, and M. Li. 2020. Age-related cytokine effects on cancer-related fatigue and quality of life in acute myeloid leukemia. J. Geriatr. Oncol. 11:402-409.

 

  • Amonoo, H.L., P.C. Johnson, T.M. Dhawale, L. Traeger, J. Rice, M.W. Lavoie, N.N. Ufere, R.M. Longley, L.E. Harnedy, M.A. Clay, C.E.W. Topping, Z. DeFilipp, Y.B.A. Chen, and A. El-Jawahri. Sharing and caring: The impact of social support on quality of life and health outcomes in hematopoietic stem cell transplantation. Cancer. 127(8):1260-1265.

 

  • Armand, P., A. Janssens, G. Gritti, J. Radford, J. Timmerman, A. Pinto, S.M. Vilchez, P. Johnson, D. Cunningham, J.P. Leonard, S.J. Rodig, P. Martin-Regueira, A. Sumbul, S. Samakoglu, H. Tang, and S.M. Ansell. 2021. Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma. Blood. 137:637-645.

 

  • Atrash, S., S.A. Ali, and S.Z. Usmani. 2021. Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma. Clin. Lymphoma Myeloma Leuk. 21:21-34.

 

  • Baeyens, A., S. Bracero, V.S. Chaluvadi, A. Khodadadi-Jamayran, M. Cammer, and S.R. Schwab. Monocyte-derived S1P in the lymph node regulates immune responses. Nature. 592(7853):290-295.

 

  • Bakouny, Z., D.A. Braun, S.A. Shukla, W.T. Pan, X. Gao, Y. Hou, A. Flaifel, S. Tang, A. Bosma-Moody, M.X. He, N. Vokes, J. Nyman, W.L. Xie, A.H. Nassar, S. Abou Alaiwi, R. Flippot, G. Bouchard, J.A. Steinharter, P.V. Nuzzo, M. Ficial, M. Sant'Angelo, J. Forman, J.E. Berchuck, S. Dudani, K. Bi, J. Park, S. Camp, M. Sticco-Ivins, L. Hirsch, S.C. Baca, M. Wind-Rotolo, P. Ross-Macdonald, M.X. Sun, G.S.M. Lee, S.L. Chang, X.X. Wei, B.A. McGregor, L.C. Harshman, G. Genovese, L. Ellis, M. Pomerantz, M.S. Hirsch, M.L. Freedman, M.B. Atkins, C.J. Wu, T.H. Ho, W.M. Linehan, D.F. McDermott, D.Y.C. Heng, S.R. Viswanathan, S. Signoretti, E.M. Van Allen, and T.K. Choueiri. 2021. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat. Commun. 12(1):808.

 

  • Bewersdorf, J.P., R.M. Shallis, and A.M. Zeidan. 2021. Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways. Blood Rev. 45:100709.

 

  • Brown, P.A., J.A. Kairalla, J.M. Hilden, Z.E. Dreyer, A.J. Carroll, N.A. Heerema, C. Wang, M. Devidas, L. Gore, W.L. Salzer, N.J. Winick, W.L. Carroll, E.A. Raetz, M.J. Borowitz, D. Small, M.L. Loh, and S.P. Hunger. FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631. Leukemia. 2021 Feb 23.

 

  • Camacho-Bydume, C., T. Wang, J.A. Sees, M. Fernandez-Vina, M.B. Abid, M. Askar, A. Beitinjaneh, V. Brown, P. Castillo, S. Chhabra, S.M. Gadalla, J.M. Hsu, M. Kamoun, A. Lazaryan, T. Nishihori, K. Page, J. Schetelig, K. Fleischhauer, S.G.E. Marsh, S. Paczesny, S.R. Spellman, S.J. Lee, and K.C. Hsu. Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. Transpl. Cell. Ther. 27(2):142.e1-142.e11.

 

  • Cao, X., B.L. Li, J. Chen, J. Dang, S.Q. Chen, E.G. Gunes, B. Xu, L. Tian, S. Muend, M. Raoof, C. Querfeld, J.H. Yu, S.T. Rosen, Y.Y. Wang, and M.Y. Feng. 2021. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer. J. Immunother. Cancer. 9(3):e002022.

 

  • Chen, H., Y.X. Zhang, A.Y. Ye, Z. Du, M. Xu, C.S. Lee, J.K. Hwang, N. Kyritsis, Z.Q. Ba, D. Neuberg, D.R. Littman, and F.W. Alt. 2020. BCR selection and affinity maturation in Peyer's patch germinal centres. Nature. 582(7812):421-425.

 

  • Chen, T.M.L., B. Harrington, J. Truxall, R. Wasmuth, A. Prouty, S. Sloan, A.M. Lehman, D. Sampath, E. Orlemans, R.A. Baiocchi, L. Alinari, J.C. Byrd, J.A. Woyach, and E. Hertlein. Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL. J. Hematol. Oncol. 14(1):36.

 

  • Coskun, A.F., G.J. Han, S. Ganesh, S.Y. Chen, X.R. Clave, S. Harmsen, S.Z. Jiang, C.M. Schurch, Y.H. Bai, C. Hitzman, and G.P. Nolan. Nanoscopic subcellular imaging enabled by ion beam tomography. Nat. Commun. 12(1):789.

 

  • Davis, R.R., B.L. Li, S.Y. Yun, A. Chan, P. Nareddy, S. Gunawan, M. Ayaz, H.R. Lawrence, G.W. Reuther, N.J. Lawrence, and E. Schonbrunn. Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof. J. Med. Chem. 64:2228-2241.

 

  • Dunn, W.G., M.X.S. Gu, M.A. Fabre, J. Cooper, J.F. Nomdedeu, L. Koumas, K. Nicolaou, J.X. Chi, P. Costeas, and G.S. Vassiliou. The PML-RARA fusion is not detectable in historical blood samples of acute promyelocytic leukaemia patients. Ann. Hematol. 2021 Mar 1.

 

  • El-Jawahri, A., J.A. Greer, E.R. Park, V.A. Jackson, M. Kamdar, S.P. Rinaldi, E.R. Gallagher, A.D. Jagielo, C.E.W. Topping, M. Elyze, B. Jones, and J.S. Temel. Psychological Distress in Bereaved Caregivers of Patients With Advanced Cancer. J. Pain Symptom Manage. 61:488-494.

 

  • Epperla, N., K.A. Ahn, M. Khanal, C. Litovich, S. Ahmed, N. Ghosh, T.S. Fenske, M.A. Kharfan-Dabaja, A. Sureda, and M. Hamadani. Impact of Reduced-Intensity Conditioning Regimens on Outcomes in Diffuse Large B Cell Lymphoma Undergoing Allogeneic Transplantation. Transpl. Cell. Ther. 27(1):58-66.

 

  • Ficial, M., O.A. Jegede, M. Sant'Angelo, Y. Hou, A. Flaifel, J.C. Pignon, D.A. Braun, M. Wind-Rotolo, M.A. Sticco-Ivins, P.J. Catalano, G.J. Freeman, A.H. Sharpe, F.S. Hodi, R.J. Motzer, C.J. Wu, M.B. Atkins, D.F. McDermott, S.A. Shukla, T.K. Choueiri, and S. Signoretti. Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clin. Cancer Res. 27:1371-1380.

 

  • Fidler, T.P., C.Y. Xue, M. Yalcinkaya, B. Hardaway, S. Abramowicz, T. Xiao, W.L. Liu, D.G. Thomas, M.A. Hajebrahimi, J. Pircher, C. Silvestre-Roig, A.G. Kotini, L.L. Luchsinger, Y. Wei, M. Westerterp, H.W. Snoeck, E.P. Papapetrou, C. Schulz, S. Massberg, O. Soehnlein, B. Ebert, R.L. Levine, M.P. Reilly, P. Libby, N. Wang, and A.R. Tall. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature. 592(7853):296-301.

 

  • Godwin, C.D., G.S. Laszlo, S. Fiorenza, E.E. Garling, T.D. Phi, O.M. Bates, C.E. Correnti, B.G. Hoffstrom, M.C. Lunn, O. Humbert, H.P. Kiem, C.J. Turtle, and R.B. Walter. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy. Leukemia. 2021 Feb 15.

 

  • Graf, S.A., R.D. Cassaday, K. Morris, J.M. Voutsinas, Q.V. Wu, S. Behnia, R.C. Lynch, E. Krakow, H. Rasmussen, T.R. Chauncey, S. Kanan, L. Soma, S.D. Smith, and A.K. Gopal. 2021. Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. Clin. Lymphoma Myeloma Leuk. 21:176-181.

 

  • Gustine, J.N., L. Xu, G. Yang, X. Liu, A. Kofides, N. Tsakmaklis, M. Munshi, M. Demos, M.L. Guerrera, K. Meid, C.J. Patterson, S. Sarosiek, A.R. Branagan, Z.R. Hunter, J.J. Castillo, and S.P. Treon. Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenstrom macroglobulinaemia. Br. J. Haematol. 2021 Mar 13

 

  • Jan, M., A.S. Sperling, and B.L. Ebert. Cancer therapies based on targeted protein degradation - lessons learned with lenalidomide. Nat. Rev. Clin. Oncol. 2021 Mar 2

 

  • Janelle V, Delisle JS. T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies. Cancers (Basel). 2021 Feb 3;13(4):598.

 

  • Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV. Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. Transplant Cell Ther. 2021 Jan;27(1):46-52. CDP Scholar Clin

 

  • Kucine N, Bergmann S, Krichevsky S, Jones D, Rytting M, Jain J, Bennett CM, Resar LMS, Mascarenhas J, Verstovsek S, Hoffman R. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia. Pediatr Blood Cancer. 2021 Mar;68(3):e28888.

 

  • Kunacheewa, C., L. Feng, E.E. Manasanch, Q. Bashir, K.K. Patel, R. Mehta, G.P. Kaufman, S. Srour, N. Saini, S.P. Iyer, S.K. Thomas, D.M. Weber, R.Z. Orlowski, M.H. Qazilbash, and H.C. Lee. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br. J. Haematol.

 

  • Laffleur, B., J. Lim, W.W. Zhang, Y.Y. Chen, E. Pefanis, J. Bizarro, C.R. Batista, L.J. Wu, A.N. Economides, J.G. Wang, and U. Basu. 2021. Noncoding RNA processing by DIS3 regulates chromosomal architecture and somatic hypermutation in B cells. Nature Genet. 53:230-+.

 

  • Lee, Y.L., K. Ito, W.C. Pi, I.H. Lin, C.S. Chu, S. Malik, I.H. Cheng, W.Y. Chen, and R.G. Roeder. 2021. Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth. Proceedings of the National Academy of Sciences of the United States of America. 118.

 

  • Lemonnier, F., V. Safar, A. Beldi-Ferchiou, A.S. Cottereau, E. Bachy, G. Cartron, V. Fataccioli, L. Pelletier, C. Robe, A. Letourneau, E. Missiaglia, S. Fourati, M.P. Moles-Moreau, A. Delmer, R. Bouabdallah, L. Voillat, S. Becker, C. Bossard, M. Parrens, O. Casasnovas, V. Cacheux, C. Regny, V. Camus, M.H. Delfau-Larue, M. Meignan, L. de Leval, P. Gaulard, and C. Haioun. 2021. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. Blood Adv. 5:539-548.

 

  • Lewis R, Bewersdorf JP, Zeidan AM. Clinical Management of Anemia in Patients with Myelodysplastic Syndromes: An Update on Emerging Therapeutic Options. Cancer Manag Res. 2021 Jan 25;13:645-657. CDP Clin Scholar

 

  • Li R, Zheng C, Wang Q, Bi E, Yang M, Hou J, Fu W, Yi Q, Qian J. Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma. Haematologica. 2021 Mar 1;106(3):838-846. TRP

 

  • Liu Y, Mei Y, Han X, Korobova FV, Prado MA, Yang J, Peng Z, Paulo JA, Gygi SP, Finley D, Ji P. Membrane skeleton modulates erythroid proteome remodeling and organelle clearance. Blood. 2021 Jan 21;137(3):398-409. CDP Scholar

 

  • Lo JA, Kawakubo M, Juneja VR, Su MY, Erlich TH, LaFleur MW, Kemeny LV, Rashid M, Malehmir M, Rabi SA, Raghavan R, Allouche J, Kasumova G, Frederick DT, Pauken KE, Weng QY, Pereira da Silva M, Xu Y, van der Sande AAJ, Silkworth W, Roider E, Browne EP, Lieb DJ, Wang B, Garraway LA, Wu CJ, Flaherty KT, Brinckerhoff CE, Mullins DW, Adams DJ, Hacohen N, Hoang MP, Boland GM, Freeman GJ, Sharpe AH, Manstein D, Fisher DE. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 Feb 17;13(581):eabd8636. CDP Scholar

 

  • Lu P, Wang S, Franzen CA, Venkataraman G, McClure R, Li L, Wu W, Niu N, Sukhanova M, Pei J, Baldwin DA, Nejati R, Wasik MA, Khan N, Tu Y, Gao J, Chen Y, Ma S, Larson RA, Wang YL. Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. Blood Cancer J. 2021 Feb 18;11(2):39. TRP

 

  • McCachren SS, Dhodapkar KM, Dhodapkar MV. Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention. Front Immunol. 2021 Feb 26;12:632564. SCOR, TRP

 

  • Miller PG, Sperling AS, Gibson CJ, Pozdnyakova O, Wong WJ, Manos MP, Buchbinder EI, Hodi FS, Ebert BL, Davids MS. A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. Haematologica. 2021 Feb 1;106(2):651-654.

 

  • Minnie SA, Hill GR. Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy? Front Immunol. 2021 Mar 12;12:651288. SCOR

 

  • Moses BS, McCullough S, Fox JM, Mott BT, Bentzen SM, Kim M, Tyner JW, Lapidus RG, Emadi A, Rudek MA, Kingsbury TJ, Civin CI. Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax. Blood Adv. 2021 Feb 9;5(3):711-724. TRP

 

  • Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, Nghiemphu L, Kaley T, Colman H, McCluskey C, Gaffey S, Smith TR, Cote DJ, Severgnini M, Yearley JH, Zhao Q, Blumenschein WM, Duda DG, Muzikansky A, Jain RK, Wen PY, Reardon DA. Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma. Clin Cancer Res. 2021 Feb 15;27(4):1048-1057.

 

  • Nelson, A., A. Kavanaugh, J. Webb, V. Jackson, N. O'Connor, B. Bhatnagar, A. Fathi, A. Brunner, J. Greer, J. Temel, T. LeBlanc, and A. El-Jawahri. 2021. Palliative care and coping in patients with acute myeloid leukemia (AML): Mediation analysis of data from a randomized clinical trial. Psycho-Oncol. 30:11-11.

 

  • Pal M, Herold MJ. CRISPR base editing applications for identifying cancer-driving mutations. Biochem Soc Trans. 2021 Feb 26;49(1):269-280. SCOR

 

  • Pan L, Hong C, Chan LN, Xiao G, Malvi P, Robinson ME, Geng H, Reddy ST, Lee J, Khairnar V, Cosgun KN, Xu L, Kume K, Sadras T, Wang S, Wajapeyee N, Müschen M. PON2 subverts metabolic gatekeeper functions in B cells to promote leukemogenesis. Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):e2016553118.

 

  • Patel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Adv. 2021 Feb 23;5(4):994-1002. CDP Clin Scholar

 

  • Petroni G, Galluzzi L. Impact of treatment schedule on the efficacy of cytostatic and immunostimulatory agents. Oncoimmunology. 2021 Feb 19;10(1):1889101. Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang)

 

  • Quaglino P, Prince HM, Cowan R, Vermeer M, Papadavid E, Bagot M, Servitjie O, Berti E, Guenova E, Stadler R, Querfeld C, Busschots AM, Hodak E, Patsatsi A, Sanches J, Maule M, Yoo J, Kevin M, Fava P, Ribero S, Zocchi L, Rubatto M, Fierro MT, Wehkamp U, Marshalko M, Mitteldorf C, Akilov O, Ortiz-Romero P, Estrach T, Vakeva L, Enz PA, Wobser M, Bayne M, Jonak C, Rubeta M, Forbes A, Bates A, Battistella M, Amel-Kashipaz R, Vydianath B, Combalia A, Georgiou E, Hauben E, Hong EK, Jost M, Knobler R, Amitay-Laish I, Miyashiro D, Cury-Martins J, Martinez X, Muniesa C, Prag-Naveh H, Stratigos A, Nikolaou V, Quint K, Ram-Wolff C, Rieger K, Stranzenbach R, Szepesi Á, Alberti-Violetti S, Felicity E, Cerroni L, Kempf W, Whittaker S, Willemze R, Kim Y, Scarisbrick JJ. Treatment of early-stage mycosis fungoides: results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2021 Apr;184(4):722-730. CDP Clin Scholar

 

  • Ramsey HE, Greenwood D, Zhang S, Childress M, Arrate MP, Gorska AE, Fuller L, Zhao Y, Stengel K, Fischer MA, Stubbs MC, Liu PCC, Boyd K, Rathmell JC, Hiebert SW, Savona MR. BET Inhibition Enhances the Antileukemic Activity of Low-dose Venetoclax in Acute Myeloid Leukemia. Clin Cancer Res. 2021 Jan 15;27(2):598-607.

 

  • Rendeiro AF, Casano J, Vorkas CK, Singh H, Morales A, DeSimone RA, Ellsworth GB, Soave R, Kapadia SN, Saito K, Brown CD, Hsu J, Kyriakides C, Chiu S, Cappelli LV, Cacciapuoti MT, Tam W, Galluzzi L, Simonson PD, Elemento O, Salvatore M, Inghirami G. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci Alliance. 2020 Dec 24;4(2):e202000955. Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang)

 

  • Richardson DR, Oakes AH, Crossnohere NL, Rathsmill G, Reinhart C, O'Donoghue B, Bridges JFP. Prioritizing the worries of AML patients: Quantifying patient experience using best-worst scaling. Psychooncology. 2021 Feb 5.

 

  • Rius B, Mesgarzadeh JS, Romine IC, Paxman RJ, Kelly JW, Wiseman RL. Pharmacologic targeting of plasma cell endoplasmic reticulum proteostasis to reduce amyloidogenic light chain secretion. Blood Adv. 2021 Feb 23;5(4):1037-1049. CDP Fellow

 

  • Rodriguez-Fraticelli AE, Weinreb C, Wang SW, Migueles RP, Jankovic M, Usart M, Klein AM, Lowell S, Camargo FD. Single-cell lineage tracing unveils a role for TCF15 in haematopoiesis. Nature. 2020 Jul;583(7817):585-589. CDP Special Fellow, Scholar

 

  • Rogers EM, Allred SC, Peifer M. Abelson kinase's intrinsically disordered region plays essential roles in protein function and protein stability. Cell Commun Signal. 2021 Feb 24;19(1):27. CDP

 

  • Sanghvi VR, Mohan P, Singh K, Cao L, Berishaj M, Wolfe AL, Schatz JH, Lailler N, de Stanchina E, Viale A, Wendel HG. NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. Cancers (Basel). 2021 Feb 5;13(4):639. SCOR, CDP

 

  • Tothova Z, Valton AL, Gorelov RA, Vallurupalli M, Krill-Burger JM, Holmes A, Landers CC, Haydu JE, Malolepsza E, Hartigan C, Donahue M, Popova KD, Koochaki S, Venev SV, Rivera J, Chen E, Lage K, Schenone M, D'Andrea AD, Carr SA, Morgan EA, Dekker J, Ebert BL. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI Insight. 2021 Feb 8;6(3):e142149. CDP Scholar, Special Fellow, 

 

  • Verma R, Branagan AR, Xu ML, Flavell RA, Dhodapkar KM, Dhodapkar MV. Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia. 2021 Feb 18.

 

  • Vitale I, Manic G, Galluzzi L. Oncosuppressive functions of PIDD1 in response to centrosome amplification. Cell Death Dis. 2021 Feb 11;12(2):175. Mantle Cell Lymphoma Research Initiative (MCL-RI, PI: Chen-Kiang)

 

  • Xia TL, Li X, Wang X, Zhu YJ, Zhang H, Cheng W, Chen ML, Ye Y, Li Y, Zhang A, Dai DL, Zhu QY, Yuan L, Zheng J, Huang H, Chen SQ, Xiao ZW, Wang HB, Roy G, Zhong Q, Lin D, Zeng YX, Wang J, Zhao B, Gewurz BE, Chen J, Zuo Z, Zeng MS. N(6)-methyladenosine-binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay. EMBO Rep. 2021 Apr 7;22(4):e50128. CDP

 

  • Yamazaki T, Bravo-San Pedro JM, Galluzzi L, Kroemer G, Pietrocola F. Autophagy in the cancer-immunity dialogue. Adv Drug Deliv Rev. 2021 Feb;169:40-50.

 

  • Yang Y, Tang Y, Gao R, Bao S, Huo Y, McKenna MT, Savona MR, Abramson RG, Landman BA. Validation and estimation of spleen volume via computer-assisted segmentation on clinically acquired CT scans. J Med Imaging (Bellingham). 2021 Jan;8(1):014004.

 

  • Ye H, Minhajuddin M, Krug A, Pei S, Chou CH, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, Pollyea DA, Christians U, Grimes HL, D'Alessandro A, Jordan CT. The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG. Cancer Discov. 2021 Feb;11(2):500-519. SCOR

 

  • Zhang P, Katzaroff AJ, Buttitta LA, Ma Y, Jiang H, Nickerson DW, Øvrebø JI, Edgar BA. The Krüppel-like factor Cabut has cell cycle regulatory properties similar to E2F1. Proc Natl Acad Sci U S A. 2021 Feb 16;118(7):e2015675118.

 

  • Zhao H, Deininger M. Eradicating residual chronic myeloid leukaemia: basic research lost in translation. Lancet Haematol. 2021 Feb;8(2):e101-e104.

 

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.